Gilead's Climb Stalls at 148th in $760M Volume Amid Therapy Jitters

On October 8, 2025, Gilead Sciences (GILD) rose 1.26% to close with a trading volume of $0.76 billion, ranking 148th in market activity for the day. The biopharmaceutical giant’s shares saw mixed momentum as investors digested recent developments in its therapeutic pipeline and regulatory landscape.

Analysts noted that Gilead’s performance was influenced by updates regarding its antiviral and oncology programs. Recent clinical data from Phase III trials for a novel HIV therapy showed improved patient outcomes compared to existing regimens. However, regulatory delays in the FDA’s review of a next-generation hepatitis B treatment created uncertainty among stakeholders. The stock’s volume contraction of 24.2% from the prior day suggested cautious positioning ahead of anticipated quarterly earnings in early November.

Strategic investors highlighted the company’s ongoing collaboration with smaller biotechs as a key growth lever. A partnership announcement with a European firm last week expanded Gilead’s gene therapy portfolio, though market participants remained focused on the commercialization timeline for these assets. Short-term volatility is expected to persist amid macroeconomic concerns and sector-wide pressure from generic drug competition.

To run this back-test accurately I first need to confirm a few practical details: 1. Universe • Are we talking about all U.S. common stocks (NYSE + NASDAQ) only? • ADRs, ETFs, pink-sheet names, etc. should they be excluded? 2. Selection rule • “Top 500 by daily trading volume” — do you mean: a) rank by $-value traded (volume × close), or b) rank purely by share volume? • Re-rank every trading day and rebuild the portfolio the same day’s close? 3. Portfolio construction • Equal-weight each of the 500 names? • Any constraints such as max position size or liquidity buffer? 4. Trading & costing assumptions • Entry at next day’s open and exit at the same day’s close (holding period = 1 day)? • Commission/slippage assumptions, if any. 5. Benchmark / performance metrics • Do you need the strategy’s raw return only, or should I also compute excess return vs. a benchmark (e.g., SPY)? • Any risk metrics (max drawdown, Sharpe, etc.) beyond cumulative return? With these clarified I can build the data-gathering plan and run the back-test from 2022-01-03 through today (2025-10-08). Let me know, and we’ll proceed right away.